ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout

August 25, 2020 Articles 7:21 pm

For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with PTSD. Rick Doblin, for years psychedelic therapy’s most prominent advocate and fundraiser, and his non-profit, MAPS, have raised millions to advance clinical trials, most recently raising $30 million to complete a Phase III study in veterans.

 

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.